Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial
Author:
Kudriavtsev Aleksandr V.1ORCID, Vakhrusheva Anna V.1ORCID, Kryuchkov Nickolay A.2, Frolova Maria E.3ORCID, Blagodatskikh Konstantin A.4, Ivanishin Taras V.13, Djonovic Milana3, Romanovskaya-Romanko Ekaterina A.5, Kovalenko Anton N.2, Lioznov Dmitry A.5, Zubkova Tatiana G.5, Teplykh Svetlana V.6, Oseshnyuk Rodion A.7, Stukova Marina A.5, Isaev Artur A.3ORCID, Krasilnikov Igor V.58
Affiliation:
1. Betuvax LLC, 121096 Moscow, Russia 2. Clinical Excellence Group LLC, 127051 Moscow, Russia 3. PJSC Human Stem Cells Institute, 129110 Moscow, Russia 4. Center of Genetics and Reproductive Medicine “Genetico”, 119333 Moscow, Russia 5. Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 Saint Petersburg, Russia 6. Professor Clinic LLC, 614070 Perm, Russia 7. Ecosafety Center LLC, 195000 Saint Petersburg, Russia 8. Biotechnology Developments LLC, 119285 Moscow, Russia
Abstract
COVID-19, being a life-threatening infection that evolves rapidly, remains a major public health concern calling for the development of vaccines with broad protection against different pathogenic strains and high immunogenicity. Aside from this, other concerns in mass immunization settings are also the scalability of production and relative affordability of the technology. In that regard, adjuvanted protein vaccines with particles mimicking the virus stand out among known vaccine technologies. The “Betuvax-CoV-2” vaccine, developed on the basis of a recombinant protein and an adjuvant, has already been tested in preclinical studies and has advanced to clinical evaluation. Open, double-blinded, placebo-controlled, randomized phase I/II clinical trial of the “Betuvax-CoV-2,” recombinant protein subunit vaccine based on the S-protein RBD fused with the Fc-fragment of IgG, was conducted to evaluate safety and immunogenicity in response to the vaccination. Methods: In the phase I/II clinical trial, 116 healthy adult men and women, ages 18–58, were enrolled: 20 in Stage I, and 96 in Stage II. In Stage I, 20 µg of the vaccine was administered intramuscularly on day 2, and either 5 µg (group 1) or 20 µg (group 2) on day 30. In Stage II, 20 µg of the vaccine was administered intramuscularly on day 2, and either 5 µg (group 3) or 20 µg (group 4) on day 30. In group 5, both injections were replaced with placebo. The primary outcome measures were safety (number of participants with adverse events throughout the study) and antigen-specific humoral immunity (SARS-CoV-2-specific antibodies measured by ELISA and CMIA). Antigen-specific cell-mediated immunity and changes in neutralizing antibodies (detected with a SARS-CoV-2 neutralization assay) were measured as a secondary outcome. The trial is registered with ClinicalTrials.gov (Study Identifier: NCT05270954). Findings: Both vaccine formulations (20 µg + 5 µg and 20 µg + 20 µg) were safe and well tolerated. Most adverse events were mild, and no serious adverse events were detected. On day 51,anti-SARS-CoV-2 total and IgG antibody titers and anti-SARS-CoV-2 neutralizing antibodies were significantly higher in the vaccine groups (both formulations) than in the placebo. A more pronounced CD4+-mediated immune response was observed in the group of volunteers administered with the 20 + 20 μg vaccine formulation. Interpretations: RBD-Fc-based COVID-19 “Betuvax-CoV-2” vaccine in doses (20 + 5 µg and 20 + 20 µg) demonstrated an excellent safety profile and induced a strong humoral response. Further research on the protective effectiveness of the “Betuvax-CoV-2” vaccine for the prevention of COVID-19 is on its way.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference26 articles.
1. World Health Organization (2022, October 19). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/. 2. Kudriavtsev, A.V., Vakhrusheva, A.V., Novoseletsky, V.N., Bozdaganyan, M.E., Shaitan, K.V., Kirpichnikov, M.P., and Sokolova, O.S. (2022). Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. Viruses, 14. 3. Krasilnikov, I.V., Kudriavtsev, A.V., Vakhrusheva, A.V., Frolova, M.E., Ivanov, A.V., Stukova, M.A., Romanovskaya-Romanko, E.A., Vasilyev, K.A., Mushenkova, N.V., and Isaev, A.A. (2022). Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2. Vaccines, 10. 4. Vakhrusheva, A.V., Kudriavtsev, A.V., Kryuchkov, N.A., Deev, R.V., Frolova, M.E., Blagodatskikh, K.A., Djonovic, M., Nedorubov, A.A., Odintsova, E., and Ivanov, A.V. (2022). SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study. Vaccines, 10. 5. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine;Polack;N. Engl. J. Med.,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|